Last reviewed · How we verify
Pegylated interferon alpha-2b
Pegylated interferon alpha-2b is a Small molecule drug developed by Emory University. It is currently FDA-approved. Also known as: Peg-Intron, PEG Interferon Alpha-2b, PEG-INTRON, PEGASYS.
Pegylated interferon alpha-2b is a protein-based drug that acts as an agonist to the interferon alpha/beta receptor. It has been studied in clinical trials for various conditions, including ulcerated melanomas, hepatitis B, and hepatitis C infections.
At a glance
| Generic name | Pegylated interferon alpha-2b |
|---|---|
| Also known as | Peg-Intron, PEG Interferon Alpha-2b, PEG-INTRON, PEGASYS, SCH 054031 |
| Sponsor | Emory University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006) (PHASE3)
- Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia (PHASE2)
- Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma (PHASE2)
- A Clinical Study of Gecacitinib Combined With Pegylated Interferon in Patients With PV (NA)
- Safety, Tolerability, and Preliminary Efficacy of Peginterferon α-2b in Combination With an Anti-PD-1 Antibody in Patients With Advanced or Metastatic Malignant Solid Tumors (NA)
- Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer (PHASE1)
- Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Relapser Genotype 2 Hepatitis C Infected Patients (PHASE3)
- A Phase 1 Study of MP-424, Peginterferon Alfa 2b, and Ribavirin in Hepatitis C (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pegylated interferon alpha-2b CI brief — competitive landscape report
- Pegylated interferon alpha-2b updates RSS · CI watch RSS
- Emory University portfolio CI
Frequently asked questions about Pegylated interferon alpha-2b
What is Pegylated interferon alpha-2b?
Who makes Pegylated interferon alpha-2b?
Is Pegylated interferon alpha-2b also known as anything else?
What development phase is Pegylated interferon alpha-2b in?
Related
- Manufacturer: Emory University — full pipeline
- Also known as: Peg-Intron, PEG Interferon Alpha-2b, PEG-INTRON, PEGASYS, SCH 054031
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing